Dry eye affects up to 16 million people in the US, and new treatments aim to mitigate the symptoms that can disrupt quality of life in these patients.

A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination eye drop containing an anti-inflammatory steroid and a quinolone antibiotic, ...

Results from the Phase III VEGA-3 trial (NCT06542497) show that significantly more patients treated with Viatris and Opus Genetics’ MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia ...

Now that summer is here and the school holidays are nearly upon us, many of us are planning time outdoors and travelling in ...

TEL AVIV, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio ...

A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination eye drop containing an anti-inflam ...

Stuart Therapeutics Announces Initial Results of Phase III Clinical Trial for ST-100 (Vezocolmitide) Ophthalmic Solution, a Novel Dry Eye Disease Candidate ...

Opus Genetics reports positive Phase 3 trial results for Phentolamine Ophthalmic Solution 0.75% in treating presbyopia.

Karen Fernandez, MD, discusses the different types of treatment currently being tested for use in dry eye disease, which affects millions in the US.

Lupin has launched a generic eye medication in the US, aimed at treating inflammation and pain. This new product is a generic ...